Yusheng Han

Director Yusheng Han purchased 731,410 shares ($6.2M) across 7 transactions at BNR; stock down 44.7% in 90 days, -78.5% from 52-week high

Yusheng Han, a director at Burning Rock Biotech, executed 7 separate purchases totaling 731,410 shares for $6,182,171.76 between June 11–26, 2026, at prices ranging from $7.45 to $9.25 and a blended average price of $8.45. The current price of $8.96 sits 78.5% below the 52-week high of $41.72, indicating significant shareholder value erosion. Han's prior purchase at this ticker on 2026-03-31 was followed by a 90-day decline of -53.5%, and his cross-ticker track record shows 0% win rate with an average 90-day return of -53.5%, suggesting a pattern of buying into sustained downtrends. The timing and scale of this multi-week accumulation at depressed levels warrants investor attention to underlying fundamentals and whether this represents management conviction or a contrarian signal in a deteriorating stock.

Director Han Yusheng buys 314,870 shares of BNR at $17.36; stock down 60.6% from 52-week high

Han Yusheng, a Director at Burning Rock Biotech, purchased 314,870 shares at $17.36 on 2026-03-31 for a total value of $5,466,143.20, increasing his holdings from 17,357,806 shares to 17,672,676 shares (+1.8%). The timing of this purchase is notable given that BNR's current price of $16.20 reflects a 60.6% decline from its 52-week high of $41.06, with the stock down 31.2% over the past 30 days alone. While the purchase price at $17.36 was above the current price, the transaction occurred against a backdrop of significant recent share-price deterioration. The acquisition rate and holding size suggest a material position with ongoing engagement, though the absence of prior trading history and fundamentals data limits ability to contextualize the transaction within broader capital allocation patterns.